Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Public ClinicalTrials.gov record NCT00110994. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase II Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Dacarbazine (DTIC) Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma
Study identification
- NCT ID
- NCT00110994
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Bayer
- Industry
- Enrollment
- 101 participants
Conditions and interventions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2005
- Primary completion
- Sep 30, 2006
- Completion
- Feb 29, 2008
- Last update posted
- Jun 7, 2015
2005 – 2008
United States locations
- U.S. sites
- 14
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Tucson | Arizona | 85724 | — |
| Not listed | Aurora | Colorado | 80045 | — |
| Not listed | Lakeland | Florida | 33805 | — |
| Not listed | Park Ridge | Illinois | 60068 | — |
| Not listed | Boston | Massachusetts | 02114 | — |
| Not listed | Boston | Massachusetts | 02115-6084 | — |
| Not listed | Boston | Massachusetts | 02215 | — |
| Not listed | St Louis | Missouri | 63110-1093 | — |
| Not listed | Omaha | Nebraska | 68114 | — |
| Not listed | Charlotte | North Carolina | 28203 | — |
| Not listed | Pittsburgh | Pennsylvania | 15232 | — |
| Not listed | Hilton Head Island | South Carolina | 29926-2739 | — |
| Not listed | Nashville | Tennessee | 37232-6307 | — |
| Not listed | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00110994, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 7, 2015 · Synced May 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00110994 live on ClinicalTrials.gov.